Login to Your Account



TxCell Lands $16M to Advance Immunotherapy for Crohn's

By Cormac Sheridan
Staff Writer

Wednesday, November 28, 2012
Continuing Europe's recent push in cell therapy development, TxCell SA raised €12.4 million (US$16. 1 million) in a Series C round to fund a Phase IIb study of its OvaSave autologous cell therapy in patients with refractory Crohn's disease.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription